Davide Campari-Milano


Q2 FY24 – Campari has caught the flu

01/08/24 -"Although Campari’s results have been relatively resilient against a backdrop of soft market dynamics, the lack of sunshine leading to a negative mix is weighing on the Italian company. ..."

Pages
54
Language
English
Published on
01/08/24
You may also be interested by these reports :
24/10/25
Heineken held its Capital Markets Day in Seville, presenting its FY30 strategy focused on transitioning from past expansion to sustainable growth. ...

23/10/25
Kerry Group delivered Q3 2025 volume growth of 3%, broadly in line with Visible Alpha consensus of +3.1%. Growth was supported by strong performances ...

22/10/25
Heineken has reported organic results in line with expectations. The Eastern region has partially offset challenges in the Western region, which is ...

16/10/25
Pernod Ricard reported a slightly larger-than-expected organic decline in Q1 25/26, impacted by ongoing destocking and soft consumer demand. However, ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO